Nov 15, 2024 / 02:00PM GMT
Goeran Forsberg - Cantargia AB - Chief Executive Officer
Thanks a lot. It's with the great pleasure we are here to present our Q3 report from Cantargia. It's been an exciting period with rich news flow. And if we quickly summarize the news flow during or after this period, we've seen that we made progress in both of our clinical programs, both in nadunolimab and the CAN10 program and in nadunolimab program, some of the material events has been that the FDA gave us clearance to start a leukemia study, which is also fully funded by a grant from the US Ministry of Defense.
We got the first results in the randomized Phase II trial more and more clearly defined when to expect, and it's going to be in the first half of 2025. So obviously, something to look forward to later on. We presented new clinical data first at the ESMO Congress on nadunolimab combination therapy after relapse PD1 inhibitor therapy. And that shows some very exciting data points, and we'll go through that in a second.
And we also did a number of clinical trials that were started in 2021, but due to changing market
Q3 2024 Cantargia AB Earnings Call Transcript
Nov 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers